MKS1 Inhibitors
MKS1 inhibitors represent a diverse array of compounds targeting key signaling pathways involved in cellular regulation. PF-4708671, an AMP-activated protein kinase (AMPK) inhibitor, can influence MKS1 indirectly by modulating cellular energy sensing. This occurs through the disruption of AMPK-dependent pathways, impacting the cellular response to energy fluctuations and, potentially, MKS1 regulation. Rapamycin, a well-known mTOR inhibitor, can indirectly affect MKS1 by disrupting the mTOR signaling pathway. By inhibiting mTOR, Rapamycin alters the downstream regulatory network associated with cellular growth and proliferation, providing a potential avenue for influencing MKS1 expression and function. U0126, an MEK1/2 inhibitor, impacts the MAPK/ERK pathway, potentially influencing MKS1 indirectly by altering phosphorylation events and transcriptional responses associated with MAPK/ERK signaling. This modulation of the MAPK/ERK pathway can contribute to the regulation of MKS1 expression and cellular responses.
Additionally, SB 203580, LY294002, SP600125, VX-745, and GSK-650394 target the p38 MAPK, PI3K/Akt, JNK, and JAK/STAT pathways, respectively. These inhibitors can indirectly impact MKS1 by disrupting the specific signaling cascades associated with stress responses, inflammation, and cytokine-mediated cellular regulation. A769662, an AMPK activator, provides an alternative approach by enhancing AMPK activity. This activator can influence MKS1 indirectly by promoting cellular energy sensing and modulating downstream pathways associated with AMPK-dependent regulation. AZD7762 and Wortmannin target CHK1/2 and PI3-kinase, respectively, affecting cell cycle checkpoints and PI3K/Akt pathways. These inhibitors can indirectly modulate MKS1 by disrupting the relevant signaling cascades associated with cell cycle regulation and survival pathways. CEP-32496, a JAK2 inhibitor, influences MKS1 indirectly by altering the JAK2/STAT-dependent signaling cascades associated with inflammation and cellular responses to cytokines. In summary, MKS1 inhibitors offer a range of mechanisms to modulate cellular pathways associated with MKS1 regulation. These compounds provide valuable tools for dissecting the intricate signaling networks that govern MKS1 expression and cellular responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
AMP-activated protein kinase (AMPK) inhibitor affecting energy homeostasis. PF-4708671 modulates AMPK activity, potentially influencing MKS1 indirectly by altering cellular energy sensing and the downstream signaling pathways associated with AMPK-dependent regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor affecting the mTOR signaling pathway. Rapamycin modulates mTOR activity, potentially influencing MKS1 indirectly by disrupting the mTOR-dependent regulatory network associated with cellular growth and proliferation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor affecting the p38 MAPK signaling pathway. SB 203580 modulates p38 MAPK activity, potentially influencing MKS1 indirectly by disrupting the p38 MAPK-dependent regulatory network associated with stress responses and inflammation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3-kinase inhibitor impacting the PI3K/Akt pathway. LY294002 modulates PI3-kinase activity, potentially influencing MKS1 indirectly by altering the PI3K/Akt-dependent signaling cascades associated with cellular survival and proliferation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the JNK signaling pathway. SP600125 modulates JNK activity, potentially influencing MKS1 indirectly by disrupting the JNK-dependent regulatory network associated with stress responses, inflammation, and apoptosis. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
JAK2 inhibitor affecting the JAK/STAT pathway. VX-745 modulates JAK2 activity, potentially influencing MKS1 indirectly by altering the JAK2/STAT-dependent signaling cascades associated with inflammation and cellular responses to cytokines. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
AMP-activated protein kinase (AMPK) activator affecting energy homeostasis. A769662 enhances AMPK activity, potentially influencing MKS1 indirectly by modulating cellular energy sensing and the downstream signaling pathways associated with AMPK-dependent regulation. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
CHK1/2 inhibitor affecting cell cycle checkpoints. AZD7762 modulates CHK1/2 activity, potentially influencing MKS1 indirectly by disrupting the cell cycle-associated signaling cascades regulated by CHK1/2-dependent mechanisms. | ||||||
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $183.00 $754.00 | 8 | |
p38 MAPK inhibitor affecting the p38 MAPK signaling pathway. GSK-650394 modulates p38 MAPK activity, potentially influencing MKS1 indirectly by disrupting the p38 MAPK-dependent regulatory network associated with stress responses and inflammation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3-kinase inhibitor impacting the PI3K/Akt pathway. Wortmannin modulates PI3-kinase activity, potentially influencing MKS1 indirectly by altering the PI3K/Akt-dependent signaling cascades associated with cellular survival and proliferation. | ||||||